

Ethiopia

Population 2018

109 million

Estimates of TB burden ^o , 2018	Number (thousands)	Rate (per 100 000 population)
Total TB incidence	165 (116–223)	151 (107–204)
HIV-positive TB incidence	7.6 (5.3–10)	7 (4.9–9.4)
MDR/RR-TB incidence ^{oo}	1.6 (1–2.2)	1.4 (0.96–2)
HIV-negative TB mortality	24 (15–36)	22 (14–33)
HIV-positive TB mortality	2.2 (1.5–3)	2 (1.4–2.8)

Estimated proportion of TB cases with MDR/RR-TB, 2018	
New cases	0.71% (0.62–0.8)
Previously treated cases	16% (14–17)

TB case notifications, 2018	
Total new and relapse	113 613
- % tested with rapid diagnostics at time of diagnosis	
- % with known HIV status	92%
- % pulmonary	69%
- % bacteriologically confirmed ^{ooo}	62%
- % children aged 0-14 years	10%
- % women	40%
- % men	50%
Total cases notified	114 233

Universal health coverage and social protection	
TB treatment coverage (notified/estimated incidence), 2018	69% (51–98)
TB patients facing catastrophic total costs	
TB case fatality ratio (estimated mortality/estimated incidence), 2018	17% (9–25)

TB/HIV care in new and relapse TB patients, 2018		Number	(%)
Patients with known HIV status who are HIV-positive		4 816	5%
- on antiretroviral therapy		4 393	91%

Drug-resistant TB care, 2018	
% of bacteriologically confirmed TB cases tested for rifampicin resistance ^{ooo}	
- New cases	80%
- Previously treated cases	100%
Laboratory-confirmed cases*	MDR/RR-TB: 741, XDR-TB: 3
Patients started on treatment**	MDR/RR-TB: 747, XDR-TB: 3
MDR/RR-TB cases tested for resistance to second-line drugs	360

Treatment success rate and cohort size		
	Success	Cohort
New cases registered in 2017	96%	113 690
Previously treated cases registered in 2017		
HIV-positive TB cases registered in 2017		
MDR/RR-TB cases started on second-line treatment in 2016	72%	703
XDR-TB cases started on second-line treatment in 2016		

TB preventive treatment, 2018	
% of HIV-positive people (newly enrolled in care) on preventive treatment	49%
% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment	22% (20–24)

TB financing, 2019	
National TB budget (US\$ millions)	94
Funding source: 11% domestic, 29% international, 60% unfunded	

^o Ranges represent uncertainty intervals

^{oo} MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin


^{ooo} Calculated for pulmonary cases only

* Includes cases with unknown previous TB treatment history

** Includes patients diagnosed before 2018 and patients who were not laboratory-confirmed


Tuberculosis profile

(Rate per 100 000 population per year)




Legend:
■ Total TB incidence
■ New and relapse TB cases notified
■ HIV-positive TB incidence

(Rate per 100 000 population per year)



Legend:
■ HIV-negative TB mortality

Notified cases by age group and sex, 2018




Legend:
■ Females
■ Males
 Incidence

Treatment success rate (%)



Legend:
■ New cases
■ Previously treated cases
■ HIV-positive
■ MDR/RR-TB
■ XDR-TB

Total budget (US\$ millions)



Legend:
■ Unfunded
■ Funded internationally
■ Funded domestically